gsk2245035
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2012 (NCT01607372)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- TLR7 and TLR8AGONIST
TLR7 and TLR8 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk2245035
- gsk2245035
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03707678 | Phase 2 | Jan 21, 2019 | GlaxoSmithKline |
| NCT02833974 | Phase 2 | Dec 5, 2016 | GlaxoSmithKline |
| NCT01788813 | Phase 2 | Mar 1, 2013 | GlaxoSmithKline |
| NCT01607372 | Phase 2 | Apr 1, 2012 | GlaxoSmithKline, PATH |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 1 | 2012 |
| PATH | Academic/Hospital | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1